Lionsgate posted strong revenue of over $724 million for its third quarter, but it wasn't enough to avoid a net loss of over $46 million. The studio's adjusted earnings fell short of analyst projections, a miss driven by soaring marketing costs for its otherwise successful film slate.
A tale of two divisions: The studio's Motion Picture division was the primary growth driver, with sales surging 35% to $421 million. But that success came at a steep price, as high marketing costs weighed on the division's bottom line. Meanwhile, Lionsgate blamed the timing of its show deliveries for a 25% dip in TV production revenue, which landed at $303 million.
Library to the rescue: The studio's quiet cash cow remains its massive 20,000-title content library. The catalog's trailing 12-month revenue climbed 10% to a new high of over $1 billion, marking the fifth consecutive quarter of record growth for the division.
Open for business: The quarter's mixed results put a spotlight on a more telling move: its signal to the market that it's ready for a deal. Lionsgate is allowing its "poison pill"—a defense designed to ward off hostile takeovers—to expire in May, making it a prime target in an industry hungry for consolidation.
While Lionsgate is betting on a strong slate of IP-driven films, the decision to lower its defenses suggests the company sees its extensive library and production capabilities as its most valuable assets in a potential sale.
